- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03588260
Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis
January 11, 2024 updated by: esra pehlivan, Istanbul Medipol University Hospital
Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis: The Relationship With Exercise Capacity, Physical Activity Level, and Quality of Life
Respiratory muscle strength, dyspnea perception, physical activity and quality of life measurements will be performed and groups will be compared in two groups consisting of patients with idiopathic pulmonary fibrosis referred to pulmonary rehabilitation clinic and healthy volunteers in similar age range.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic will be included in the study.
In addition, a healthy adult control group will be established from similar age groups.
The two groups will be compared in terms of outcome measures.The study outcome measurements are maximum inspiratory/expiratory muscle strength , international physical activity questionaire, modified Medical Research Council dyspnea scale, Short form 36 quality of lide questionaire, fatigue severity scale, six minute walking test.
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Arif Balcı
- Email: arifbalci2000@yahoo.com
Study Contact Backup
- Name: Esra Pehlivan, PhD
- Phone Number: +905058527913
- Email: fztesrakambur@yahoo.com
Study Locations
-
-
Zeytinburnu
-
Istanbul, Zeytinburnu, Turkey, 34200
- Yedikule Chest Disease Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic will be included in the study.
In addition, a healthy adult control group will be established from similar age groups.
The two groups will be compared in terms of outcome measures.
Description
Inclusion Criteria:
- Between the ages of 18-70
- Patients signing informed consent form
- Patients diagnosed with idiopathic pulmonary fibrosis.
Exclusion Criteria:
- Patients who use steroids for less than 1 year
- The patient does not want to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Idiopathic pulmonary fibrosis
The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic.
|
no intervention - cross-sectional observational only
|
Healthy subjects
The healthy adults without additional disease
|
no intervention - cross-sectional observational only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum inspiratory muscle pressure
Time Frame: 15 minutes
|
The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC.
Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely, and then tried to breath in as hard as possible.
The patient was allowed to rest for about a minute and the maneuver was repeated five times.
Verbal or visual feedback was provided after each maneuver.
The aim is that the variability between measurements is less than 10 cm H2O.
The maximum value was obtained.
|
15 minutes
|
Maximum expiratory muscle pressure
Time Frame: 15 minutes
|
The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC.
Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely, and then tried to breath in as hard as possible.
The patient was allowed to rest for about a minute and the maneuver was repeated five times.
Verbal or visual feedback was provided after each maneuver.
The aim is that the variability between measurements is less than 10 cm H2O.
The maximum value was obtained.
|
15 minutes
|
The distance covered in six-minute walk test
Time Frame: 10 minutes
|
The test was conducted in a 30-meter corridor in line with American Thoracic Society (ATS) guidelines.
Patients were told that they should walk as fast as they can walk.
Before and after the test, oxygen saturation, heart rate, Borg fatigue rating, and walking distance were recorded.
|
10 minutes
|
International Physical Activity Questionnaire
Time Frame: 15 minutes
|
The International Physical Activity Questionnaire (IPAQ) was developed as an instrument for cross-national monitoring of physical activity and inactivity.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.
|
15 minutes
|
The Quality of Life Questionaire
Time Frame: 20 minutes
|
Short Form 36
|
20 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The modified Medical Research Council (mMRC) scale
Time Frame: 3 minutes
|
Dyspnea perceptions during daily life activities will assess according to the modified Medical Research Council (mMRC) scale.
The mMRC Dyspnea Scale is best used to establish baseline functional impairment due to dyspnea attributable to respiratory disease; tracking the mMRC over time or with therapeutic interventions is of less certain clinical utility.The severity of dyspnea is rated on a scale of 0 to 4. "0" means no dyspnea perception, "4" means severe dyspnea perception.
|
3 minutes
|
The fatigue severity scale
Time Frame: 15 minutes
|
|
15 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2018
Primary Completion (Actual)
December 30, 2023
Study Completion (Actual)
December 30, 2023
Study Registration Dates
First Submitted
July 4, 2018
First Submitted That Met QC Criteria
July 4, 2018
First Posted (Actual)
July 17, 2018
Study Record Updates
Last Update Posted (Actual)
January 12, 2024
Last Update Submitted That Met QC Criteria
January 11, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IPF_MIP/MEP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on no intervention - cross-sectional observational only
-
Ahram Canadian UniversityRecruiting
-
Northumbria Healthcare NHS Foundation TrustCompleted
-
Aga Khan UniversityCompleted
-
University Medicine GreifswaldUniversity Medical Center Rostock; University of Applied Sciences Neubrandenburg and other collaboratorsCompletedChronic Pancreatitis | Short Bowel Syndrome | Liver CirrhosesGermany
-
Centro Cardiologico MonzinoCompletedDepression | Quality of Life | Anxiety | Emotional Stress | Self-care | Chronic Cardiovascular DiseaseItaly
-
American Medical AssociationJohns Hopkins University; University of California, San Francisco; University... and other collaboratorsUnknownPhysician Work Motivation
-
Alexandria UniversityRecruitingMyalgic EncephalomyelitisEgypt
-
University of Massachusetts, AmherstTufts University; Harvard University; UNICEFCompletedStunting | Adolescent Development | UndernutritionUnited States
-
Chinese University of Hong KongHospital Authority of Hong Kong (Bradbury Hospice)Completed
-
Ahram Canadian UniversityRecruiting